Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Subpopulation analyses performed for enoxaparin vs. heparin trials

March 27, 2001

DuPont Pharmaceuticals' roxifiban study amended

March 26, 2001

Berlex presents novel anticoagulants

March 22, 2001

vWF MAb inhibits stent thrombosis at high shear rates

March 21, 2001

Antithrombotic action of DX-9065a and enoxaparin compared

March 21, 2001

Combined roxifiban/Innohep has improved safety/efficacy ratio

March 21, 2001

Argatroban enters phase II for ischemic stroke

March 16, 2001

XV-454 compares favorably to abciximab in flow models of thrombosis in vitro

March 16, 2001

Human factor Xa inhibitor JTV-803 is a promising orally active antithrombotic agent

March 14, 2001

Single-injection thrombolytic introduced in the E.U.

March 13, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...